196 related articles for article (PubMed ID: 26683645)
1. Chorea in a patient with cryopyrin-associated periodic syndrome.
Schwarzbach CJ; Schmitt WH; Szabo K; Bäzner H; Hennerici MG; Blahak C
Neurology; 2016 Jan; 86(3):241-4. PubMed ID: 26683645
[TBL] [Abstract][Full Text] [Related]
2. Delayed reactivation of chronic infantile neurologic, cutaneous, articular syndrome (CINCA) in a patient with somatic mosaicism of CIAS1/NLRP3 gene after withdrawal of anti-IL-1 beta therapy.
Paloni G; Pastore S; Tommasini A; Lepore L; Taddio A
Clin Exp Rheumatol; 2015; 33(5):766. PubMed ID: 26316056
[No Abstract] [Full Text] [Related]
3. Anakinra for cryopyrin-associated periodic syndrome.
Koné-Paut I; Galeotti C
Expert Rev Clin Immunol; 2014 Jan; 10(1):7-18. PubMed ID: 24308832
[TBL] [Abstract][Full Text] [Related]
4. A novel mutation in the CIAS1/NLRP3 gene associated with an unexpected phenotype of cryopyrin-associated periodic syndromes.
Insalaco A; Prencipe G; Buonuomo PS; Ceccherini I; Bracaglia C; Pardeo M; Nicolai R; De Benedetti F
Clin Exp Rheumatol; 2014; 32(1):123-5. PubMed ID: 24144430
[TBL] [Abstract][Full Text] [Related]
5. Neonatal urticaria: Could it be CAPS?
Cutts L; Parslew R; Eustace K
Pediatr Dermatol; 2018 Nov; 35(6):e420-e421. PubMed ID: 30187963
[TBL] [Abstract][Full Text] [Related]
6. [Muckle-Wells syndrome caused by a new cryopyrin mutation: effective treatment with interleukin-1 antagonist].
Rameev VV; Kozlovskaia LV; Bogdanova MV
Ter Arkh; 2012; 84(6):53-9. PubMed ID: 22997920
[TBL] [Abstract][Full Text] [Related]
7. Muckle-Wells syndrome without mutation in exon 3 of the NLRP3 gene, identified by evidence of excessive monocyte production of functional interleukin 1β and rapid response to anakinra.
Sabroe RA; Stokes CA; Parker LC; Higgins K; Prince LR; Sabroe I
Clin Exp Dermatol; 2013 Dec; 38(8):874-7. PubMed ID: 23889084
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome.
Kuemmerle-Deschner JB; Tyrrell PN; Koetter I; Wittkowski H; Bialkowski A; Tzaribachev N; Lohse P; Koitchev A; Deuter C; Foell D; Benseler SM
Arthritis Rheum; 2011 Mar; 63(3):840-9. PubMed ID: 21360513
[TBL] [Abstract][Full Text] [Related]
9. [Description of a case of hyperkinetic movement disorder in neonatal onset multisystem inflammatory disease or chronic infantile neurologic cutaneous and articular syndrome].
Gómez-Camello Á; Ortego-Centeno N
Rev Neurol; 2014 Jan; 58(2):94-6. PubMed ID: 24399627
[TBL] [Abstract][Full Text] [Related]
10. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
Koné-Paut I; Galeotti C
Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
[TBL] [Abstract][Full Text] [Related]
11. Description of a new family with cryopyrin-associated periodic syndrome: risk of visual loss in patients bearing the R260W mutation.
Alejandre N; Ruiz-Palacios A; García-Aparicio AM; Blanco-Kelly F; Bermúdez S; Fernández-Sanz G; Romero FI; Aróstegui JI; Ayuso C; Jiménez-Alfaro I; Herrero-Beaumont G; Sánchez-Pernaute O
Rheumatology (Oxford); 2014 Jun; 53(6):1095-9. PubMed ID: 24501247
[TBL] [Abstract][Full Text] [Related]
12. Cryopyrin-associated periodic syndromes: diagnosis and management.
Miyamae T
Paediatr Drugs; 2012 Apr; 14(2):109-17. PubMed ID: 22335455
[TBL] [Abstract][Full Text] [Related]
13. Two adult siblings with atypical cryopyrin-associated periodic syndrome due to a novel M299V mutation in NLRP3.
Verma D; Eriksson P; Sahdo B; Persson A; Ejdebäck M; Särndahl E; Söderkvist P
Arthritis Rheum; 2010 Jul; 62(7):2138-43. PubMed ID: 20506209
[TBL] [Abstract][Full Text] [Related]
14. Muckle-Wells treatment with anakinra.
Eungdamrong J; Boyd KP; Meehan SA; Latkowski JA
Dermatol Online J; 2013 Dec; 19(12):20720. PubMed ID: 24365011
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
Landmann EC; Walker UA
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.
Anton J; Calvo I; Fernández-Martin J; Gamir ML; Merino R; Jimenez-Treviño S; Sevilla B; Cabades F; Bou R; Arostegui JI
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S67-71. PubMed ID: 26243511
[TBL] [Abstract][Full Text] [Related]
17. Neonatal treatment of CINCA syndrome.
Paccaud Y; Berthet G; Von Scheven-Gête A; Vaudaux B; Mivelaz Y; Hofer M; Roth-Kleiner M
Pediatr Rheumatol Online J; 2014; 12():52. PubMed ID: 25584041
[TBL] [Abstract][Full Text] [Related]
18. Twenty year follow up of a patient with a new de-novo NLRP3 mutation (S595G) and CINCA syndrome.
Kanariou M; Dracou C; Spanou K; Möller J; Rösen-Wolff A; Schuster V; Roesler J
Klin Padiatr; 2009; 221(6):379-81. PubMed ID: 19890791
[TBL] [Abstract][Full Text] [Related]
19. Severe cryopyrin-associated periodic syndrome first characterized by early childhood-onset sensorineural hearing loss - Case report and literature review.
Hui A; Johnson LB; Greemberg R; Penney L; Ramsey SE
Int J Pediatr Otorhinolaryngol; 2019 May; 120():68-72. PubMed ID: 30772614
[TBL] [Abstract][Full Text] [Related]
20. [Cryopyrin-associated periodic syndromes (CAPS)].
Yagüe J
Med Clin (Barc); 2011 Jan; 136 Suppl 1():1-2. PubMed ID: 21596179
[No Abstract] [Full Text] [Related]
[Next] [New Search]
